News IRLAB Therapeutics AB

Stocks

IRLAB A

SE0012675361

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-17 EDT			5-day change	1st Jan Change
1.288 ^SEK	-6.12%		-7.87%	-34.62%

07-08	Irlab board member James Gamgort buys shares for just under SEK 0.3m	FW
06-30	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI

All News

Mentions Relevance

07-10	IRLAB Therapeutics : rights issue is registered – conversion of BTA into shares	PU
07-08	Irlab board member James Gamgort buys shares for just under SEK 0.3m	FW
06-30	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI
06-30	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB	AQ
06-30	IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln	RE
06-30	Irlab Therapeutics Raises SEK76.5 Million from Oversubscribed Rights Offering	MT
06-30	Irlab rights issue oversubscribed	FW
06-16	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
06-16	Irlab highlights positive data for mesdopetam	FW
06-16	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
06-16	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
06-08	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
06-05	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI
06-05	Irlab rights issue now 91 percent secured	FW
06-05	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
06-05	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ
06-03	IRLAB Participates at Aktiedagarna in Stockholm on June 9	AQ
06-03	IRLAB participates at Aktiedagarna in Stockholm on June 9.	AQ
05-06	IRLAB Therapeutics : Financial Report (irlab q1 2026 eng final)	PU
05-06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
05-06	Irlab reports growth in revenue and operating profit	FW
05-06	IRLAB Therapeutics : publishes interim report for the period January – March 2026	PU
05-06	IRLAB publishes interim report for the period January - March 2026	AQ
05-06	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Irlab launches SEK 68 million rights issue	FW